APA-viite

Veeraraghavan, J., Gutierrez, C., Sethunath, V., Mehravaran, S., Giuliano, M., Shea, M. J., . . . Schiff, R. (2021). Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer.

Chicago-tyylinen lähdeviittaus

Veeraraghavan, Jamunarani, et al. "Neratinib Plus Trastuzumab Is Superior to Pertuzumab Plus Trastuzumab in HER2-positive Breast Cancer Xenograft Models." NPJ Breast Cancer 2021.

MLA-viite

Veeraraghavan, Jamunarani, et al. "Neratinib Plus Trastuzumab Is Superior to Pertuzumab Plus Trastuzumab in HER2-positive Breast Cancer Xenograft Models." NPJ Breast Cancer 2021.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.